Drew Yashar

Endpoint Health is a Precision-First therapeutics company dedicated to addressing unmet needs in immune-mediated chronic and acute diseases. We leverage our proprietary artificial intelligence (AI) platform and combine companion diagnostics with therapeutics to develop precision therapies. Our vision is a world in which all patients get the best treatment possible for their unique biology and disease.

Zafrens is a therapeutics company pioneering an ultra-high throughput platform to isolate, culture, image, and sequence millions of cells per day. The proprietary platform allows for full characterization of diverse cell populations, as well as directly correlating molecular profiles (DNA, RNA, protein) to cell phenotype and function. The company’s mission is to unlock the full story of every cell to accelerate drug discovery.

High throughput engineering of cell lines to enhance the design and manufacture of next-generation therapeutics.

Mythic Therapeutics is a product-platform company that is pioneering a powerful new approach to improving the effectiveness of antibody-drug conjugates (ADCs) and other antibody-based therapeutics. Our technology dramatically increases therapeutic potency without compromising safety, thereby unlocking the full potential of targeted therapies against a broad array of tumor targets. At Mythic, we focus on patient-centered science and are driven to leave a lasting impact on cancer care.

Capital Factory is the center of gravity for entrepreneurs in Texas, the number one startup state in the U.S. Thousands of entrepreneurs, programmers and designers gather day and night, in-person and online for meetups, classes and coworking. With boots on the ground in Austin, Dallas, Houston, and San Antonio, we meet the best entrepreneurs in Texas and introduce them to their first investors, employees, mentors and customers. According to Pitchbook, Capital Factory has been the most active investor in Texas since 2010.

Endpoint Health is a Precision-First therapeutics company dedicated to addressing unmet needs in immune-mediated chronic and acute diseases. We leverage our proprietary artificial intelligence (AI) platform and combine companion diagnostics with therapeutics to develop precision therapies. Our vision is a world in which all patients get the best treatment possible for their unique biology and disease.

Alix Ventures: Driving Patient Impact - Supporting early stage Life Science startups engineering biology to drive radical advances in human health Born from our collective experience as founders, we set out to build the fund we wanted to raise from... Thesis: Life Sciences is experiencing rapid innovation with the rise of new generation of companies known as “TechBio” (Merging technology & biology), a change we believe is leading to some of the most impactful solutions in decades. Our passion is to help build transformative companies ahead of this revolution to significantly impact the quality & effectiveness of patient care. We aim to partner with passionate, accomplished founders who possess unique insights to solve some of the world’s most daring problems facing us in Life Sciences. Team: Our entire team is built of Life Science Founders with experience in raising capital, scaling teams, running labs, partnering with Pharma, & the many fires that consist of operating an early stage company. Founders, we’d love to partner with you along the journey & help translate daunting ideas into world shaping innovations - here’s to a better brighter future for patients! SAB: Composed of Bioengineering PhDs turned Founders, our Scientific Advisory Board provides deep technical expertise & fluency across a wide variety of Life Science sub-domains from platforms for “Novel Applications” (Therapeutics/Diagnostics) to “Bio-Economy Infrastructure” (Tools/Services/Manufacturing). Let’s talk science! Support: Helping our founders is our utmost priority. To tackle the many challenges ahead, we’ve curated a full platform of resources to help with customer introductions, fundraising, & team building, amongst others. In addition, dedicated to supporting our portfolio is our extensive network of industry executives spanning Top 25 Pharma, major health systems, & large Payors.

Zafrens is a therapeutics company pioneering an ultra-high throughput platform to isolate, culture, image, and sequence millions of cells per day. The proprietary platform allows for full characterization of diverse cell populations, as well as directly correlating molecular profiles (DNA, RNA, protein) to cell phenotype and function. The company’s mission is to unlock the full story of every cell to accelerate drug discovery.

High throughput engineering of cell lines to enhance the design and manufacture of next-generation therapeutics.